JP2012505257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505257A5 JP2012505257A5 JP2011531261A JP2011531261A JP2012505257A5 JP 2012505257 A5 JP2012505257 A5 JP 2012505257A5 JP 2011531261 A JP2011531261 A JP 2011531261A JP 2011531261 A JP2011531261 A JP 2011531261A JP 2012505257 A5 JP2012505257 A5 JP 2012505257A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- hydrogen
- use according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1ccc2N(*)*CCN(*)C*c2c1 Chemical compound *c1ccc2N(*)*CCN(*)C*c2c1 0.000 description 5
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10485408P | 2008-10-13 | 2008-10-13 | |
| US61/104,854 | 2008-10-13 | ||
| US15768709P | 2009-03-05 | 2009-03-05 | |
| US61/157,687 | 2009-03-05 | ||
| PCT/US2009/060557 WO2010045265A1 (en) | 2008-10-13 | 2009-10-13 | Compositions and methods for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012505257A JP2012505257A (ja) | 2012-03-01 |
| JP2012505257A5 true JP2012505257A5 (cg-RX-API-DMAC7.html) | 2012-11-08 |
Family
ID=42106858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531261A Pending JP2012505257A (ja) | 2008-10-13 | 2009-10-13 | 多発性硬化症治療のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20110195049A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2355660A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012505257A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010045265A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010031054A1 (en) | 2008-09-15 | 2010-03-18 | Biovista, Inc. | Compositions and methods for treating epilepsy |
| US8545892B2 (en) | 2009-06-26 | 2013-10-01 | Nano Pharmaceutical Laboratories, Llc | Sustained release beads and suspensions including the same for sustained delivery of active ingredients |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| RU2448685C2 (ru) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза |
| WO2013153179A1 (en) * | 2012-04-11 | 2013-10-17 | Lipoxen Technologies Limited | Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis |
| DK2665471T3 (en) | 2011-01-19 | 2018-03-19 | Pathologica Llc | ORAL PHARMACEUTICAL DOSAGE FORMS WITH MANAGED RELEASE COMPREHENSIVE MGBG |
| HK1198278A1 (en) * | 2011-07-28 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013130422A1 (en) | 2012-02-27 | 2013-09-06 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
| UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
| CN105163730B (zh) * | 2013-01-08 | 2018-10-30 | 帕萨罗杰卡有限公司 | 用于治疗脱髓鞘疾病的方法和组合物 |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| EP3244881A4 (en) | 2015-01-12 | 2018-08-15 | Nano Pharmaceutical Laboratories LLC | Layered sustained-release microbeads and methods of making the same |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| CA2490804C (en) * | 2002-06-28 | 2016-12-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| US20050065219A1 (en) * | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| MX2008000811A (es) * | 2005-07-28 | 2008-03-18 | Squibb Bristol Myers Co | Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina. |
| WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| AU2007254325B2 (en) * | 2006-05-15 | 2012-05-10 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US20100099700A1 (en) * | 2006-09-20 | 2010-04-22 | David Hung | Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als) |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| MX2009012788A (es) * | 2007-05-25 | 2010-01-14 | Medivation Neurology Inc | Metodos y composiciones para estimular celulas. |
| EP2085120A1 (en) * | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
-
2009
- 2009-10-13 EP EP20090821140 patent/EP2355660A4/en not_active Ceased
- 2009-10-13 US US13/123,660 patent/US20110195049A1/en not_active Abandoned
- 2009-10-13 WO PCT/US2009/060557 patent/WO2010045265A1/en not_active Ceased
- 2009-10-13 JP JP2011531261A patent/JP2012505257A/ja active Pending
-
2014
- 2014-04-14 US US14/251,818 patent/US20150111919A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512165A5 (cg-RX-API-DMAC7.html) | ||
| RU2445312C2 (ru) | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR | |
| JP2010077141A5 (cg-RX-API-DMAC7.html) | ||
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| JP2006514611A5 (cg-RX-API-DMAC7.html) | ||
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| JP2017518334A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512531A5 (cg-RX-API-DMAC7.html) | ||
| JP2015528471A5 (cg-RX-API-DMAC7.html) | ||
| JP2007145875A5 (cg-RX-API-DMAC7.html) | ||
| JP2015512406A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517883A5 (cg-RX-API-DMAC7.html) | ||
| JP2013521303A5 (cg-RX-API-DMAC7.html) | ||
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| JP2010532373A5 (cg-RX-API-DMAC7.html) | ||
| CN1812812B (zh) | 降血清胆固醇药或者动脉粥样硬化的预防或治疗药 | |
| CO6612204A2 (es) | Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina | |
| JP2014505108A5 (cg-RX-API-DMAC7.html) | ||
| JP2010511631A5 (cg-RX-API-DMAC7.html) | ||
| JP2012502915A5 (cg-RX-API-DMAC7.html) | ||
| JP2013522368A5 (cg-RX-API-DMAC7.html) | ||
| JP2008539250A (ja) | アテローム性動脈硬化症を処置するための方法 | |
| NZ608375A (en) | Pharmaceutical combination of an mtor catalytic inhibitor and an allosteric mtor inhibitor | |
| EA201401042A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| RU2019112148A (ru) | Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени |